Trenbolone

In vitro: Muscle-derived stem cells were prepared from the skeletal muscle of fetal calf at day 180 of gestation and treated with or without trenbolone (10 nM), a synthetic analog of testosterone, in a myogenic medium. Trenbolone treatment increased the protein levels of MyoD and myosin heavy chain, as well as the androgen receptor content. In vivo: In both intact and orchiectomized animals, all TREN (renbolone-enanthate) doses and supraphysiological testosterone-enanthate augmented androgen-sensitive levator ani/bulbocavernosus muscle mass by 35-40% above shams (P <= 0.001) and produced a dose-dependent partial protection against orchiectomy-induced total and trabecular bone mineral density losses (P < 0.05) and visceral fat accumulation (P < 0.05). Stage of development was increased among larvae in the 1 ng/L MGA + 10 ng/L 17alpha-TB treatment group and significantly decreased among those in the 500 ng/L 17alpha-TB treatment. Total body mass and snout-vent length of X. laevis larvae were significantly reduced in the 100 ng/L MGA and 100 ng/L MGA + 500 ng/L 17alpha-TB treatment groups.

(+)-Trenbolone, beta-Trenbolone

C18H22O2

>98%